



## CYFLUENT REAL WORLD TEST RESULTS\_B1

Plan Report ID Number:

Developer Name: Cyfluent

Product Name(s): Cyfluent

Version Number(s): 3.2.9

Certified Health IT Product List (CHPL) ID(s): 0015ET7SML1PUC3

Developer Real World Testing Plan Page URL: [https://www.cyfluentphr.com/ Files/CURES/](https://www.cyfluentphr.com/Files/CURES/)

### SUMMARY OF TESTING METHODS AND KEY FINDINGS

Case management logs and system logs were reviewed to ensure the export function is operating properly and to determine the frequency of use. Log files obtained during Real World Testing were used for analysis in several areas to validate the proper operation of the export. This test methodology tested for the conformance of the implementation.

Criteria § 170.315(b)(1) Transitions of care, § 170.315(b)(2) Clinical information reconciliation and incorporation, § 170.315(b)(7) Security tags - summary of care – send, and § 170.315(b)(8) Security tags - summary of care – receive, was tested by reviewing system logs where it records the activity of the provider when sending and receiving secure information.

Testing was conducted using client data and synthetic data due to low usage by clients.

### STANDARDS UPDATES (INCLUDING STANDARDS VERSION ADVANCEMENT PROCESS (SVAP) AND UNITED STATES CORE DATA FOR INTEROPERABILITY (USCDI))

Products certified with voluntary SVAP or USCDI standards.

Standard (and version)
All standards versions are those specified in USCDI v1. The developer used SVAP to update its (e)(1) module to support the new version of the Direct transport protocol (now known as Secure Health Transport) during the testing period.

### CARE SETTING(S)



- Ambulatory Care

## METRICS AND OUTCOMES

### CRITERIA AND ASSOCIATED CRITERIA, METRIC, OUTCOMES AND CHALLENGES

- **§ 170.315(b)(1) Transitions of care**
  - *Measurement:* % Provider can Send and receive, validate and display, and create Transitions of Care
  - *Outcome:* 100% success
  - *Challenges:* low usage, therefore testing was performed using synthetic data in addition to client data
  - *Relied upon software:* Secure Exchange Solutions
- **§ 170.315(b)(2) Clinical information reconciliation and incorporation**
  - *Measurement:* % Provider - general requirements met, correct patient data, reconciliation, system verification
  - *Outcome:* 100% success
  - *Challenges:* low usage, therefore testing was performed using synthetic data in addition to client data
- **§ 170.315(b)(7) Security tags - summary of care – send**
  - *Measurement:* % sending security tag
  - *Outcome:* 100% success
  - *Challenges:* low usage, therefore testing was performed using synthetic data in addition to client data
- **§ 170.315(b)(8) Security tags - summary of care – receive**
  - *Measurement:* % receiving security tags
  - *Outcome:* 100% success
  - *Challenges:* low usage, therefore testing was performed using synthetic data in addition to client data

## KEY MILESTONES

Key Milestone	Care Setting	Date/Timeframe
Release of documentation for the Real-World Testing to be provided to authorized representatives and	Ambulatory Care	December 2022



providers. This includes surveys, specific instructions on what to look for, how to record issues encountered, and Customer Agreements.		
Collection of information as laid out by the plan for the period.		<i>January 2023</i>
Planned System updates to allow for collection of data after a SVAP update.		<i>February 2023</i>
Follow-up with providers and authorized representatives to understand any issues		<i>Quarterly 2023</i>
End of Real World Testing period/final collection of all data for analysis		<i>January 2024</i>
Analysis and report creation		<i>January 2024</i>
Submit Real World Testing report to ACB (Drummond)		<i>February 2024</i>

**ATTESTATION**

This Real World Testing Results report is complete with all required elements, including measures that address all certification criteria and care settings. All information in this plan is up to date and fully addresses the health IT developer’s Real World Testing requirements.

Authorized Representative Name: Gwendolyn Thomas

Authorized Representative Email: gthomas@cyfluent.com

Authorized Representative Phone: (800)648-4836

Authorized Representative Signature: *Gwendolyn Thomas*

Date: 1/30/2024